ATAI:NASDAQ
AtaiBeckley Inc
4,16 US$
arrow_upward
+0,97%(+0,040) 1K
4,16 US$
0,00% (0,00)
bedtimeYopilgandan keyin
Savdolar yopilgan: 30-apr, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoATAI tikeri uchun statistika yaratilmoqda...
Ochish
4,12 US$
Yuqori
4,18 US$
Past
4,01 US$
Bozor kapitali
1,53 mlrd
Oʻrtacha hajm
6,58 mln
Hajmi
4,18 mln
52 haftalik eng yuqori
6,72 US$
52 haftalik eng past
1,29 US$
Aksiya boʻyicha daromad
-2,91 US$
Beta
1,57
Muomaladagi aksiyalar
366,92 mln
Xodimlar soni
99
Yangiliklar
Internetdagi manbalardan
StockStory
·
1 daqiqa oldin
Asure Software’s (NASDAQ:ASUR) Q1 CY2026 Sales Top Estimates
Stock Titan
·
45 daqiqa oldin
Eureka-led Estrella (NASDAQ: ESLA) details 59.3% control and board pay
Yahoo Finance
·
1 soat oldin
The Ensign Group (NASDAQ:ENSG) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
Advisor Perspectives
·
1 soat oldin
Moving Averages of the Ivy Portfolio and S&P 500: April 2026
Profil
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
AtaiBeckley Inc haqida
AI kontentda xatolar boʻlishi mumkin. Batafsil